Schizophrenia

Schizophrenia is a chronic psychotic disorder characterized by disturbances in thought, perception, emotion, and behavior, significantly impairing an individual’s perception of reality.

Epidemiology

Schizophrenia is a disorder with similar prevalence rates worldwide. The lifetime prevalence is approximately 1% of the population. However, this rate can rise to as high as 1.5% in urban areas. Onset typically occurs between ages 15 and 25 in men and between 25 and 35 in women, with women often experiencing a more favorable disease course. Cross-cultural studies show that the type of symptoms and societal perception of the illness vary according to cultural norms.

Etiology

The exact cause of schizophrenia remains unknown; however, it is recognized as a multifactorial disorder involving the interaction of genetic, biological, environmental, and psychosocial factors. The interplay of these factors leads to the development of the illness, with symptoms varying from individual to individual.

Genetic Factors

Schizophrenia is a disorder with a clear familial predisposition. While the general population prevalence is 1%, the risk increases to about 10% if a first-degree relative has schizophrenia, and up to 50% in monozygotic twins. Polygenic risk scores and genome-wide association studies (GWAS) indicate that multiple genes contribute small effects to the disease.

Neurodevelopmental and Biological Factors

Neuronal migration abnormalities and abnormal brain development during the prenatal period increase the risk of schizophrenia. Neuroimaging studies have identified enlarged lateral ventricles, reduced volume of the prefrontal cortex, and hippocampal atrophy.

The strongest neurochemical evidence relates to the dopamine hypothesis. Excessive dopaminergic activity in the mesolimbic pathway is associated with positive symptoms, while reduced dopamine activity in the mesocortical pathway is linked to negative and cognitive symptoms. Additionally, dysfunctions in the glutamate and serotonin systems also play a role in the pathophysiology.

Environmental Factors

Viral infections during pregnancy, birth complications, malnutrition, early-life trauma, childhood neglect, and abuse increase the risk of schizophrenia. Research has also associated social stressors such as urban upbringing, migration, and ethnic minority status with the illness.

Symptoms and Signs

Symptoms of schizophrenia are generally classified into three main categories: positive, negative, and cognitive. These symptoms may not manifest identically in all patients and can change over time.

Positive Symptoms

These arise from the perception or thought of events or objects that are not real. Hallucinations are typically paranoid in content. Auditory hallucinations are the most common, occurring in approximately 70% of patients.

Negative Symptoms

These reflect the loss of normal functions. Key examples include anhedonia (inability to experience pleasure), alogia (reduced speech), avolition (loss of motivation), and flat affect.

Cognitive Symptoms

Deficits are observed in attention, working memory, and executive functions. Cognitive testing has shown that individuals with schizophrenia perform approximately 30% lower than healthy controls. These symptoms can lead to persistent functional impairments in employment, education, and social life.

Disease Course and Clinical Subtypes

Schizophrenia typically progresses through prodromal, acute (active), and residual phases. The DSM-5 no longer classifies subtypes such as paranoid or catatonic, instead viewing schizophrenia as a spectrum disorder. Academic studies indicate that 20–30% of patients show partial recovery, while 40% experience a chronic course marked by recurrent episodes.

Diagnostic Process

Diagnosis relies on standardized classification systems such as DSM-5 or ICD-11. To establish a diagnosis, symptoms must persist for at least six months, with at least one month of active-phase symptoms (positive symptoms).

In differential diagnosis, the following conditions must be carefully considered:

• Bipolar disorder: Psychotic symptoms occur only during mood episodes.
• Schizoaffective disorder: Psychotic and mood symptoms occur simultaneously and concurrently.
• Substance-induced psychotic disorder: Symptoms are directly attributable to the effects of a substance.

Treatment Approaches

The primary goals of schizophrenia treatment are to control symptoms, prevent relapses, and enhance functional capacity. Treatment requires a multidisciplinary approach combining pharmacological and psychosocial interventions.

Pharmacological Treatment

Antipsychotics are effective in suppressing positive symptoms.

• First-generation antipsychotics: Haloperidol, fluphenazine (D₂ receptor antagonists)
• Second-generation antipsychotics: Risperidone, olanzapine, quetiapine (D₂ and 5-HT₂A antagonists)

Second-generation antipsychotics achieve symptom control in approximately 60–80% of cases. However, metabolic syndrome, weight gain, and cardiovascular risks occur in up to 20% of patients.

Psychosocial Interventions

In addition to medication, individual psychotherapy, family therapy, social skills training, psychoeducation, rehabilitation programs, and supportive services play a crucial role in treatment. Involvement of family members significantly improves treatment adherence and reduces hospitalization rates. Psychosocial support is essential for reintegrating individuals into society and maintaining social functioning.

• Psychoeducation
• Family therapy
• Social skills training
• Vocational rehabilitation
• Community-based support programs

These interventions can reduce hospitalization rates by up to 40%.

Social Impact and Stigma

Schizophrenia is a mental disorder frequently misunderstood and subject to widespread stigma in society. A lack of public knowledge about the illness negatively affects patients’ social lives. Research has shown that approximately 50% of individuals diagnosed with schizophrenia experience social isolation. Negative and inaccurate portrayals in the media exacerbate societal stigma, leading to discrimination in employment, housing, and access to healthcare. Stigma also impairs treatment adherence and social functioning.

The primary caregiving responsibility for individuals with schizophrenia is typically assumed by family members. This places a long-term psychological, social, and economic burden on caregivers. Multiple studies indicate that over 60% of family caregivers experience burnout. In this context, developing supportive services for families is essential. Psychoeducation programs, individual and family counseling, and support groups are vital tools for reducing caregiver burden and improving patients’ quality of life.

Quality of Life and Functioning

Despite pharmacological and psychosocial interventions, full restoration of quality of life is not always achieved in schizophrenia. Negative symptoms—such as emotional blunting and loss of motivation—and cognitive impairments—such as deficits in attention, memory, and executive functioning—make it difficult for individuals to maintain daily functioning and re-engage in social life.

Therefore, in the treatment of schizophrenia, the goal must extend beyond symptom reduction to actively supporting social integration. Rehabilitation programs aimed at improving functioning, including social skills training, vocational rehabilitation, and supported employment initiatives, are critical for enabling individuals to sustain independent lives and enhance their overall quality of life.